138786-93-3

Basic information

• Product Name: methyl 1-(β-D-2',3',5'-tri-O-benzoylribofuranosyl)-4-iodo-pyrazole-3-carboxylate
• Synonyms: methyl 1-(β-D-2',3',5'-tri-O-benzoylribofuranosyl)-4-iodo-pyrazole-3-carboxylate
• CAS NO: 138786-93-3
• Molecular Weight: 696.452
• Mol File: 138786-93-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 1-(β-D-2',3',5'-tri-O-benzoylribofuranosyl)-4-iodo-pyrazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-(β-D-2',3',5'-tri-O-benzoylribofuranosyl)-4-iodo-pyrazole-3-carboxylate(138786-93-3)
• EPA Substance Registry System: methyl 1-(β-D-2',3',5'-tri-O-benzoylribofuranosyl)-4-iodo-pyrazole-3-carboxylate(138786-93-3)

Safety Data

• Hazardous Substances Data: 138786-93-3(Hazardous Substances Data)

Upstream product

• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 136944-79-1 4-iodo-1H-pyrazole-3-carboxylic acid methyl ester 

Downstream Products

• 1002761-62-7 methyl 4-phenylethynyl-1-(2',3',5'-tribenzoyl-β-D-ribofuranosyl)pyrazole-3-carboxylate 
• 1002761-61-6 methyl 4-propynyl-1-(2',3',5'-tribenzoyl-β-D-ribofuranosyl)pyrazole-3-carboxylate 
• 138787-01-6 methyl 4-iodo-1-β-D-ribofuranosyl-pyrazole-3-carboxylate 
• 138787-01-6 4-iodo-1-β-D-ribofuranosylpyrazole-3-carboxamide 

Relevant articles and documents

A New Direct Glycosylation of Pyrimidine, Pyrazole, Imidazole and Purine Heterocycles via their N-tetrahydropyranyl (THP) Derivatives

Pyrimidine, pyrazole, imidazole and purine N-tetrahydropyranyl (THP) derivatives have been converted in one-pot and in a regio- and stereo-selective manner into the corresponding β-D-2',3',5'-tri-O-benzoyl ribofuranosyl nucleoside derivatives on treatment with 1-β-acetyl-2',3',5'-tri-O-benzoyl-ribofuranose, hexamethyldisilazane (HMDS), trimethylsilyl chloride (TMSCl), and trimethylsilyl triflate (TMST).

Pyrazole-Related Nucleosides. Synthesis and Antiviral/Antitumor Activity of Some Substituted Pyrazole and Pyrazolo-1,2,3-triazin-4-one Nucleosides

Several pyrazole and pyrazolo-1,2,3-triazin-4-one ribonucleosides were prepared and tested for antiviral/antitumor activities.Appropriate heterocyclic bases were prepared by standard methodologies.Glycosylation of pyrazoles 6a-e,g,i and pyrazolo-1,2,3-triazin-4-ones 12f-l mediated bu silylation with hexamethylsilazane, with 1-β-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose gave in good yields the corresponding glycosides 7a-e,g, 8g,i 13f,h,k, and 14f, but could not be applied to compounds 12g,i,j,l.To overcome this occurrence, a different strategy involvi ng the preparation, diazotization, and in situ cyclization of opportune pyrazole glycosides 9 and 10 was reguired.Moreover derivatives having the general formula 5 were considered not only as synthetic intermediates in the synthesis of 3 but also as carbon bioisosteres of ribavirin 4.All compounds were evaluated in vitro for cytostatic and antiviral activity.The pyrazolo-1,2,3-triazin-4-one nucleosides that resulted were substantially devoid of any activity; only 15h,k showed a moderate cytostatic activity against T-cells.However, pyrazole nucleosides 9b,c,e were potent and selective cytotoxic agents against T-lymphocytes, whereas 9e showed a selective, although not very potent, activity against coxsackie B1.